All In Biotech

Drug Trial Radar · NCT07313891

A Study of Adjuvant NDV-01 (Sustained-release Gemcitabine-docetaxel) for the Treatment of Intermediate Risk NMIBC Following TURBT

A Phase 3, Randomized Study Evaluating the Efficacy and Safety of NDV-01 Versus Observation in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (BOOST)

Last checked: Nov 20, 2026Latest source record: Mar 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

WithdrawnPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Withdrawn

Enrollment

0

Actual

Start

May 1, 2026

Primary completion

Sep 1, 2029

Study completion Nov 1, 2029

Sponsor

Lead sponsor
Relmada Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Jan 2, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 3, open-label, randomized trial designed to evaluate the DFS of TURBT followed by NDV-1 (sustained-release gemcitabine-docetaxel) versus TURBT followed by surveillance for the treatment of participants with IR-NMIBC.

Conditions

  • Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive)
  • Bladder (Urothelial, Transitional Cell) Cancer
  • Urothelial Carcinoma Bladder
  • Urologic Cancer

Interventions

  • NDV-01 (sustained-release gemcitabine-docetaxel)Drug

    Intravesical instillation of NDV-01 (sustained-release gemcitabine-docetaxel)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To compare DFS between study armsTime frame: From date of randomization to at least 2 years of follow-up assessing for DFS events.

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.